首页> 外文期刊>Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry >Selective up-regulation of functional mu-opioid receptor splice variants by chronic opioids
【24h】

Selective up-regulation of functional mu-opioid receptor splice variants by chronic opioids

机译:慢性阿片类药物选择性上调功能性阿片受体剪接变体

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We recently reported (Verzillo, etal. J. Neurochem: 130, 790-796, 2014) that chronic systemic morphine selectively up-regulates mRNA encoding two C-terminal -opioid receptor (MOR) splice variants, MOR-1C1 and MOR-1B2 (MOR-1B2/-1C1). Given the known disconnects between changes in levels of mRNA and corresponding protein, it is essential to directly demonstrate that chronic opioid treatment elevates functional MOR-1B2/-1C1 protein prior to inferring relevance of these MOR variants to spinal opioid tolerance mechanisms. Accordingly, we investigated the ability of chronic opioid exposure to up-regulate MOR protein in Chinese hamster ovary cells stably transfected with rat MOR variants MOR-1B2, MOR-1C1, or MOR-1 (considered to be the predominant MOR). Findings revealed that chronic treatment with the clinically relevant opioids morphine, oxycodone and hydrocodone substantially up-regulated membrane MOR-1B2/-1C1 protein. This up-regulation was abolished by the protein synthesis inhibitor cycloheximide, eliminating contributions from receptor redistribution. The increment in MOR-1B2/-1C1 protein was paralleled by a significant increment in opioid agonist-stimulated GTPS-binding (reflective of increased aggregate MOR G protein coupling) indicating that up-regulated MOR-1B2/-1C1 represented functional receptors. Strikingly, these tolerance-associated adaptations of MOR-1B2/-1C1 differed considerably from those of MOR-1. Antithetical regulation of MOR-1B2/-1C1 and MOR-1 by chronic opioids has significant implications for the design of new therapeutic agents to counteract opioid analgesic tolerance and accompanying addiction. Since chronic opioids induce MOR-1B2/-1C1 up-regulation in spinal cord of males, but not females, elucidating cellular compartments and intracellular pathways mediating MOR-1B2/-1C1 up-regulation and defining their unique signaling attributes would enable a precision medicinal approach to pain management and addiction therapy.
机译:我们最近报道(Verzillo,etal。J. Neurochem:130,790-796,2014),慢性全身性吗啡选择性上调编码两个C末端阿片受体(MOR)剪接变体MOR-1C1和MOR-1B2的mRNA (MOR-1B2 / -1C1)。鉴于已知的mRNA和相应蛋白质水平变化之间的脱节,在推断这些MOR变异体与脊髓阿片耐受机制的相关性之前,直接证明慢性阿片类药物治疗可提高功能性MOR-1B2 / -1C1蛋白至关重要。因此,我们研究了慢性阿片类药物暴露上调了大鼠MOR变体MOR-1B2,MOR-1C1或MOR-1(被认为是主要的MOR)稳定转染的中国仓鼠卵巢细胞中MOR蛋白的能力。研究结果表明,使用临床上相关的阿片类药物吗啡,羟考酮和氢可酮进行的慢性治疗大大上调了膜MOR-1B2 / -1C1蛋白。蛋白质合成抑制剂环己酰亚胺消除了这种上调,消除了受体重新分布的作用。 MOR-1B2 / -1C1蛋白的增加与阿片类激动剂刺激的GTPS结合的显着增加平行(反映了增加的MOR G蛋白偶联总量),表明MOR-1B2 / -1C1上调代表功能性受体。令人惊讶的是,MOR-1B2 / -1C1与公差相关的适应与MOR-1显着不同。慢性阿片类药物对MOR-1B2 / -1C1和MOR-1的相反调节,对设计新型药物以抵消阿片类药物的镇痛耐受性和成瘾性具有重要意义。由于慢性阿片类药物在男性而非女性的脊髓中诱导MOR-1B2 / -1C1上调,因此阐明介导MOR-1B2 / -1C1上调的细胞区室和细胞内通路并定义其独特的信号传导特性将使精确药物治疗成为可能。疼痛管理和成瘾疗法的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号